Taken together, these results suggested that the c-myc promoted NSCLC tumor growth in vitro and in vivo, and pharmacological inhibition of c-myc/miR-150 pathway would be a promising anti-cancer therapy for NSCLC. The gene discussed is MYC; the disease is neoplasm.